L
L. William Traverso
Researcher at Virginia Mason Medical Center
Publications - 96
Citations - 8071
L. William Traverso is an academic researcher from Virginia Mason Medical Center. The author has contributed to research in topics: Pancreatitis & Pancreatic duct. The author has an hindex of 40, co-authored 96 publications receiving 7356 citations.
Papers
More filters
Journal ArticleDOI
Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)
Moritz N. Wente,Claudio Bassi,Christos Dervenis,Abe Fingerhut,Dirk J. Gouma,Jakob R. Izbicki,John P. Neoptolemos,Robert Padbury,Michael G. Sarr,L. William Traverso,Charles J. Yeo,Markus W. Büchler +11 more
TL;DR: The International Study Group of Pancreatic Surgery (ISGPS) developed an objective and generally applicable definition with grades of delayed gastric emptying (DGE) based primarily on severity and clinical impact as discussed by the authors.
Journal ArticleDOI
Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.
Mark P. Callery,Kenneth J. Chang,Elliot K. Fishman,Mark S. Talamonti,L. William Traverso,David C. Linehan +5 more
TL;DR: Patients without distant metastases and no evidence of tumor extension to the SMV and portal vein and clear fat planes around the celiac axis, the hepatic artery, and SMA should be categorized as having localized and resectable cancers.
Journal ArticleDOI
Endoscopic transpapillary therapy for disrupted pancreatic duct and peripancreatic fluid collections
Richard A. Kozarek,Ball Tj,David J. Patterson,Patrick C. Freeny,John A. Ryan,L. William Traverso +5 more
TL;DR: The transpapillary treatment of ongoing pancreatic ductal disruption with or without fluid collection has the potential to obviate surgery in some patients, change an urgent surgical procedure into an elective one, or even assist the surgeon in the performance of intraoperative pancreatography.
Journal ArticleDOI
Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma
TL;DR: Overall survival may be improved for patients with adenocarcinoma in the pancreatic head using an adjuvant interferon-based chemoradiation protocol, and actuarial 2-year and 5-year overall survival rates suggest a potential for improved long-term survival.
Journal ArticleDOI
Intraductal neoplasms of the pancreas
TL;DR: In this paper, a group of pancreatic tumors have been termed intraductal papillary mucinous tumors (IPMT), which are demonstrated by pancreatography to reside in the main pancreatic duct (MPD) or side branch ducts (SBD). Lesions of IPMT result in abdominal pain or pancreatitis symptoms.